Maximise your virus uptake with transduction enhancers. Restricted uptake of virus particles often lowers the success of gene or short hairpin ribonucleic acid (shRNA) expression and requires the application of higher viral titers. However, increasing the number of viruses to boost expression can lead to toxic side effects in many cell types and makes the application unnecessarily costly.

SIRION BIOTECH’s unique LentiBOOST™ product was developed to specifically enhance the efficiency of viral gene transfer into difficult-to-transduce mammalian and rodent cell. Virus uptake is significantly increased without toxicity.

LentiBOOST™ increases lentiviral transduction of difficult cell types such as T-cells or B-cells. It is said to be a real gamechanger for chimeric antigen receptor T-cell therapy (CAR-T) cell experiments and research and development (R&D).

LentiBOOST™ is a highly effective, non-cytotoxic chemical lentiviral transduction enhancer for preclinical and clinical applications. As universal acting (receptor-independent) adjuvant it can be applied to a wide range of clinically relevant cell types including CD34+ hematopoietic stem cells (HSC), primary T-cells and NK cells.

These unique features make it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.

LentiBOOST™ is available in pharmaceutical grade for use in preclinical research and process development, as well as for evaluation studies. Licensing options for research use, development and commercial use are available.

LentiBOOST™ is also available in good manufacturing practice (GMP) grade for use in clinical stage protocols. It is currently included in Phase III and I/II clinical trials in the US and Europe. Licensing options for commercial use and development are available.